关于 "Rasnadi Panchdashakam Kwatha "治疗阿马瓦塔(类风湿性关节炎)的临床研究

Megha Kumawat, Pramod Kumar Mishra, Brahmanand Sharma
{"title":"关于 \"Rasnadi Panchdashakam Kwatha \"治疗阿马瓦塔(类风湿性关节炎)的临床研究","authors":"Megha Kumawat, Pramod Kumar Mishra, Brahmanand Sharma","doi":"10.46607/iamj0511112023","DOIUrl":null,"url":null,"abstract":"The disease Amavata can concern the result of a combination of Ama and Vata due to Mandagni. According to the clinical features, Amavata very closely resembles the Rheumatoid Arthritis. According to modern science, Amavata considered an autoimmune condition known as Rheumatoid Arthritis (RA), results in chronic joint inflammation. The prevalence of RA is 0.8% globally. According to a survey of community prevalence, women experience the condition at a 3:1 ratio to men. Without regard of sex, religion and other factors like occupation, a total of 40 individuals with the defining signs and symptoms of Amavata were chosen for this research trial. In the present clinical practice, Rasnadipanchdashakam Kwatha was given orally, 20 ml twice a day for 45 days. Results revealed statistically substantial reductions in Sandhishoola 61.76%, Sandhishotha 42.16%, and Sandhijadyata 49.41%. Additionally, results for Angmarda 52.11%, Aruchi 51.38%, Trishna 51.61%, Alasya 63.01%, Gaurava 50%, Jwara 58.92%, Apaka 59.42%. The overall results of the study were 53.97%.","PeriodicalId":169675,"journal":{"name":"International Ayurvedic Medical Journal","volume":"9 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A CLINICAL STUDY ON ‘RASNADI PANCHDASHAKAM KWATHA’ IN THE MANAGEMENT OF AMAVATA (RHEUMATOID ARTHRITIS)\",\"authors\":\"Megha Kumawat, Pramod Kumar Mishra, Brahmanand Sharma\",\"doi\":\"10.46607/iamj0511112023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The disease Amavata can concern the result of a combination of Ama and Vata due to Mandagni. According to the clinical features, Amavata very closely resembles the Rheumatoid Arthritis. According to modern science, Amavata considered an autoimmune condition known as Rheumatoid Arthritis (RA), results in chronic joint inflammation. The prevalence of RA is 0.8% globally. According to a survey of community prevalence, women experience the condition at a 3:1 ratio to men. Without regard of sex, religion and other factors like occupation, a total of 40 individuals with the defining signs and symptoms of Amavata were chosen for this research trial. In the present clinical practice, Rasnadipanchdashakam Kwatha was given orally, 20 ml twice a day for 45 days. Results revealed statistically substantial reductions in Sandhishoola 61.76%, Sandhishotha 42.16%, and Sandhijadyata 49.41%. Additionally, results for Angmarda 52.11%, Aruchi 51.38%, Trishna 51.61%, Alasya 63.01%, Gaurava 50%, Jwara 58.92%, Apaka 59.42%. The overall results of the study were 53.97%.\",\"PeriodicalId\":169675,\"journal\":{\"name\":\"International Ayurvedic Medical Journal\",\"volume\":\"9 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Ayurvedic Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46607/iamj0511112023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ayurvedic Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46607/iamj0511112023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

阿马瓦塔(Amavata)病可能是由于曼达尼(Mandagni)引起的阿马(Ama)和瓦塔(Vata)共同作用的结果。根据临床特征,阿马瓦塔与类风湿关节炎非常相似。根据现代科学,Amavata 被认为是一种自身免疫性疾病,即类风湿性关节炎(RA),会导致慢性关节炎症。类风湿性关节炎在全球的发病率为 0.8%。根据一项社区患病率调查,女性与男性的患病比例为 3:1。在不考虑性别、宗教信仰和职业等其他因素的情况下,本次研究试验共选择了 40 名具有阿马瓦塔症状和体征的患者。在目前的临床实践中,口服 Rasnadipanchdashakam Kwatha,每次 20 毫升,每天两次,持续 45 天。结果显示,从统计学角度来看,Sandhishoola 61.76%、Sandhishotha 42.16%、Sandhijadyata 49.41%的发病率大幅下降。此外,Angmarda 52.11%、Aruchi 51.38%、Trishna 51.61%、Alasya 63.01%、Gaurava 50%、Jwara 58.92%、Apaka 59.42%。研究的总体结果为 53.97%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A CLINICAL STUDY ON ‘RASNADI PANCHDASHAKAM KWATHA’ IN THE MANAGEMENT OF AMAVATA (RHEUMATOID ARTHRITIS)
The disease Amavata can concern the result of a combination of Ama and Vata due to Mandagni. According to the clinical features, Amavata very closely resembles the Rheumatoid Arthritis. According to modern science, Amavata considered an autoimmune condition known as Rheumatoid Arthritis (RA), results in chronic joint inflammation. The prevalence of RA is 0.8% globally. According to a survey of community prevalence, women experience the condition at a 3:1 ratio to men. Without regard of sex, religion and other factors like occupation, a total of 40 individuals with the defining signs and symptoms of Amavata were chosen for this research trial. In the present clinical practice, Rasnadipanchdashakam Kwatha was given orally, 20 ml twice a day for 45 days. Results revealed statistically substantial reductions in Sandhishoola 61.76%, Sandhishotha 42.16%, and Sandhijadyata 49.41%. Additionally, results for Angmarda 52.11%, Aruchi 51.38%, Trishna 51.61%, Alasya 63.01%, Gaurava 50%, Jwara 58.92%, Apaka 59.42%. The overall results of the study were 53.97%.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信